MedTrace Logo

Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)

NCT02081729 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2018-08-29

No results posted yet for this study

Summary

VZV is one of the important opportunistic infection in transplant recipients.Until now, there is no laboratory method to stratify the risk of VZV reactivation after solid organ transplantation. Theoretically, VZV-specific cell-mediate immune response before solid organ transplantation will further categorize the patients into high or low risk of VZV development after solid organ transplantation. The investigators thus evaluate the usefulness of VZV-specific ELISPOT assay in kidney transplant candidates to predict the development of VZV infection after kidney transplantation.

Conditions

  • Kidney Transplantation

Sponsors & Collaborators

  • Korea Advanced Institute of Science and Technology

    collaborator OTHER

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Sung-Han Kim, MD · Asan Medical Center

Eligibility

Min Age
16 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02081729 on ClinicalTrials.gov